Skip to main content
profile image
Selected Works of Sally Lord
Article
MIC-1/GDF15 in Barrett's oesophagus and oesophageal adenocarcinoma
British Journal of Cancer (2015)
  • Oliver Fisher, St Vincent's Centre for Applied Medical Research
  • Angelique Levert-Mignon, St Vincent's Centre for Applied Medical Research
  • Ka Ki Michelle Lee-Ng, St Vincent’s Centre for Applied Medical Research
  • Sally Lord, The University of Notre Dame Australia
  • Natalia Botelho, St Vincent’s Centre for Applied Medical Research
  • Dan Falkenback, Lund University
  • Melissa Thomas, St Vincent’s Centre for Applied Medical Research
  • Yuri Bobryshev, St. Vincents Centre for Applied Medical Research
  • David Whiteman, Queensland Institute of Medical Research
  • D Brown, St. Vincents Centre for Applied Medical Research
  • Samuel Breit, St. Vincents Centre for Applied Medical Research
  • Reginald Lord, The University of Notre Dame Australia
Link Find in your library
Abstract
Background: Biomarkers are needed to improve current diagnosis and surveillance strategies for patients with Barrett’s
oesophagus (BO) and oesophageal adenocarcinoma (OAC). Macrophage inhibitory cytokine 1/growth differentiation factor 15
(MIC-1/GDF15) tissue and plasma levels have been shown to predict disease progression in other cancer types and was therefore
evaluated in BO/OAC.
Methods: One hundred thirty-eight patients were studied: 45 normal oesophagus (NE), 37 BO, 16 BO with low-grade dysplasia
(LGD) and 40 OAC.
Results: Median tissue expression of MIC-1/GDF15 mRNA was X25-fold higher in BO and LGD compared to NE (Po0.001); twofold
higher in OAC vs BO (P¼0.039); and 47-fold higher in OAC vs NE (Po0.001). Relative MIC-1/GDF15 tissue expression 4720
discriminated between the presence of either OAC or LGD vs NE with 94% sensitivity and 71% specificity (ROC AUC 0.86, 95% CI
0.73–0.96; Po0.001). Macrophage inhibitory cytokine 1/growth differentiation factor 15 plasma values were also elevated in
patients with OAC vs NE (Po0.001) or BO (P¼0.015). High MIC-1/GDF15 plasma levels (X1140 pg ml1) were an independent
predictor of poor survival for patients with OAC (HR 3.87, 95% CI 1.01–14.75; P¼0.047).
Conclusions: Plasma and tissue levels of MIC-1/GDF15 are significantly elevated in patients with BO, LGD and OAC. Plasma
MIC-1/GDF15 may have value in diagnosis and monitoring of Barrett’s disease.
Disciplines
Publication Date
2015
DOI
10.1038/bjc.2015.100
Citation Information
Fisher, O., Levert-Mignon, A., Lord, S., Lee-Ng, K., Botelho, N., Falkenback, D., Thomas, M., Bobryshev, Y., Whiteman, D., Brown, D., Breit, S., and Lord, R. (2015). MIC-1/GDF15 in Barrett's oesophagus and oesophageal adenocarcinoma. British Journal of Cancer, 112(8), 1384-1391. DOI: 10.1038/bjc.2015.100